<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03824522</url>
  </required_header>
  <id_info>
    <org_study_id>261603</org_study_id>
    <nct_id>NCT03824522</nct_id>
  </id_info>
  <brief_title>A Post Marketing Surveillance Study for ADYNOVATE in South Korea</brief_title>
  <official_title>A Post Marketing Surveillance Study for ADYNOVATE in South Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and describe hemostatic effectiveness
      in patients receiving ADYNOVATE in routine clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Throughout the duration of patient participation of 6 months. Entire study period will be 72 months.</time_frame>
    <description>Serious adverse events and non-serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>Throughout the duration of patient participation of 6 months. Entire study period will be 72 months.</time_frame>
    <description>Serious adverse events and non-serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of inhibitor titers for FVIII antibodies</measure>
    <time_frame>Throughout the duration of patient participation of 6 months. Entire study period will be 72 months.</time_frame>
    <description>By titer levels, high and lower titer categories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treated bleeds</measure>
    <time_frame>Throughout the duration of patient participation of 6 months. Entire study period will be 72 months.</time_frame>
    <description>Number of treated bleeds throughout the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADYNOVATE units required for bleed resolution</measure>
    <time_frame>At bleed resolution, throughout the duration of patient participation of 6 months. Entire study period will be 72 months.</time_frame>
    <description>Number of ADYNOVATE units required for bleed resolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ADYNOVATE infusions needed for the treatment of bleeding episodes</measure>
    <time_frame>At bleed resolution, throughout the duration of patient participation of 6 months. Entire study period will be 72 months.</time_frame>
    <description>The number of ADYNOVATE infusions needed for each bleeding episode is determined by the participant, his/her caregiver, and/or clinician treating the participant, and is based upon the participant's response to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostatic effectiveness assessment of bleeding episodes treated with ADYNOVATE during prophylaxis treatment</measure>
    <time_frame>Throughout the duration of patient participation of 6 months. Entire study period will be 72 months.</time_frame>
    <description>Using a 4-point ordinal scale (Excellent, Good, Fair, or None)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostatic effectiveness of ADYNOVATE for participants on an on-demand regimen</measure>
    <time_frame>At bleed resolution, throughout the duration of patient participation of 6 months. Entire study period will be 72 months.</time_frame>
    <description>Using a 4-point ordinal scale (Excellent, Good, Fair, or None)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of perioperative effectiveness of ADYNOVATE</measure>
    <time_frame>Throughout the duration of patient participation of 6 months. Entire study period will be 72 months.</time_frame>
    <description>Using a 4-point ordinal scale (Excellent, Good, Fair, or None)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in laboratory results</measure>
    <time_frame>Throughout the duration of patient participation of 6 months. Entire study period will be 72 months.</time_frame>
    <description>Number of clinically significant changes in laboratory results</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>All Study Participants</arm_group_label>
    <description>All participants enrolled will be treated with ADYNOVATE for hemophilia A at the time of enrollment according to a regimen determined by the study site treating physician/investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADYNOVATE</intervention_name>
    <description>Pegylated recombinant human factor VIII</description>
    <arm_group_label>All Study Participants</arm_group_label>
    <other_name>PEGylated rFVIII</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hemophilia A patients in South Korea who have been prescribed ADYNOVATE.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

        Participants with a diagnosis of hemophilia A who have been prescribed ADYNOVATE according
        to the investigator's judgment shall be included in this study if:

          -  The participant or legally authorized representative has given written informed
             consent to participate in the study.

          -  The participant is indicated for treatment according to the ADYNOVATE South Korea
             prescribing information (PI).

        Exclusion Criteria

        Participants should be excluded from this study if:

          -  The participant or legally authorized representative does not wish to participate in
             the study.

          -  Any of the contraindications included in the PI for ADYNOVATE apply.

          -  Participant is enrolled in an interventional trial using an investigational product
             other than ADYNOVATE.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82-53-200-5704</phone>
      <email>phojyk@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ji Yooun Kim, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>42472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82-53-650-4248</phone>
      <email>ejchoi2@cu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Eunjin Choi, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82-10-3740-9149</phone>
      <email>CJ@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Chuhl Joo Lyu, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82-10-4618-3918</phone>
      <email>pysmd@khnmc.or.kr</email>
    </contact>
    <investigator>
      <last_name>YoungShil Park, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kim Hugh Chul Internal Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>05538</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82-2-478-0300</phone>
      <email>hughkim2@naver.com; hughkim7@naver.com</email>
    </contact>
    <investigator>
      <last_name>Hugh Chul Kim, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea Hemophilia Foundation (Seoul)</name>
      <address>
        <city>Seoul</city>
        <zip>06641</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82-2-3473-6107</phone>
      <email>gowho@daum.net</email>
    </contact>
    <investigator>
      <last_name>Ki-Young Yoo, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82-10-9709-9256</phone>
      <email>sang@uuh.ulsan.kr</email>
    </contact>
    <investigator>
      <last_name>Sang Kyun Park, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BAX 855</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

